Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06267391 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

A NA study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Endogenex.

Recruiting
Registry status
NA
Development phase
264
Enrollment target
20
Study locations

NCT06267391 is a NA study of Diabetes Mellitus, Type 2 and Diabetes that is actively recruiting participants, run by Endogenex. The registered enrollment target is 264 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06267391, a NA study of Diabetes Mellitus, Type 2 and Diabetes, is actively recruiting participants, sponsored by Endogenex.

RECRUITING
Registry status
NA
Development phase
264 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.

Conditions Studied

Diabetes Mellitus, Type 2 Diabetes Type 2 Diabetes Type 2 Diabetes Mellitus Type2diabetes

Interventions

  • DEVICE ReCET Treatment
  • DEVICE Sham Procedure

Study Locations (20)

Florida

  • Velocity Clinical Research, Hallandale Beach - Hallandale
  • Mayo Clinic - Jacksonville
  • Universal Axon Clinical Research LLC - Miami
  • University of Miami - Miami
  • Quantum Clinical Research - Miami Beach
  • West Orange Endocrinology - Ocoee
  • Advent Health - Orlando
  • Orlando Health - Orlando
  • Health Synergy Clinical Research - West Palm Beach

California

  • Velocity Clinical Research, Gardena - Gardena
  • Cedars-Sinai Medical Center - Los Angeles
  • UCLA - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Digestive Health Institute - Newport Beach
  • Velocity Clinical Research, Panorama City - Panorama City

Alabama

  • University of Alabama - Birmingham
  • Central Alabama Research - Birmingham

Iowa

  • Heartland Medical Research, Inc. - Clive
  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Illinois

  • NorthShore University Health System - Evanston

Maryland

  • John Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 264 participants
Start Date 2024-05-01
Est. Completion 2026-10-01
Phase NA

Sponsor

Endogenex

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06267391

The ClinicalTrials.gov registry entry for NCT06267391 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The listed sponsor is Endogenex, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which ReCET Treatment is the first listed.

NCT06267391 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT06267391 about?

NCT06267391 is a clinical study titled "Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes". This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.

What is the current status of trial NCT06267391?

This trial is currently recruiting. It is a NA study. The enrollment target is 264 participants. The study started on 2024-05-01. Estimated completion is 2026-10-01.

What conditions does trial NCT06267391 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus, Type2diabetes.

What interventions are being tested in trial NCT06267391?

The interventions under investigation include: ReCET Treatment (DEVICE), Sham Procedure (DEVICE).

Who is sponsoring clinical trial NCT06267391?

This trial is sponsored by Endogenex, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06267391 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.